CEO Vipin Garg highlighted the imminent readout of the IMPACT Phase 2b NASH trial, stating "we are confident of achieving the trial’s key efficacy and safety objectives" and emphasized that if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback